Related Experiment Video

Updated: Aug 15, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

Wen-Zhen Gu1, Ingrid Joseph, Yi-Chun Wang

  • 1Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA.

Anti-Cancer Drugs
|October 14, 2005
PubMed

Insights

ABT-100, a potent farnesyltransferase inhibitor (FTI), shows significant preclinical anti-tumor activity against various carcinomas by inhibiting Ras signaling. This FTI also suppresses vascular endothelial growth factor (VEGF) and angiogenesis, making it a promising candidate for clinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ras mutations are prevalent in human carcinomas (20-30%), driving tumor growth.
  • Farnesyltransferase inhibitors (FTIs) offer a therapeutic strategy by indirectly inhibiting Ras.
  • Targeting Ras signaling is crucial for developing novel cancer treatments.

Purpose of the Study:

  • To evaluate the preclinical anti-tumor activity of ABT-100, a novel FTI.
  • To compare ABT-100 with existing clinical candidates.
  • To elucidate the mechanisms underlying ABT-100's efficacy.

Main Methods:

  • Preclinical animal models of solid tumors.
  • Assessment of tumor growth inhibition.
  • Analysis of vascular endothelial growth factor (VEGF) mRNA and protein levels.
  • Evaluation of anti-angiogenic effects.

Main Results:

  • ABT-100 demonstrated broad inhibition of solid tumor growth in preclinical models.
  • ABT-100 exhibited high selectivity, potency, and oral bioavailability.
  • Significant suppression of VEGF expression and secretion was observed.
  • Inhibition of angiogenesis was confirmed in vivo.

Conclusions:

  • ABT-100 is a potent and selective FTI with promising preclinical anti-tumor activity.
  • ABT-100 warrants further clinical evaluation for cancer treatment.
  • The anti-angiogenic effects of ABT-100, mediated by VEGF suppression, contribute to its therapeutic potential.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...